TKG (Drug Discovery) Overview
- Year Founded
-
2022
- Status
-
Private
- Employees
-
2
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
8
TKG (Drug Discovery) General Information
Description
Developer of cancer immunotherapy drugs designed to induce innate immunity. The company specializes in using hairpin-shaped nucleic acid drugs and miRNA that is specifically overexpressed in cancer cells as a biomarker, forming a nucleic acid aggregate that is recognized as a foreign substance inside target disease cells, triggering innate immunity and leading to the death of cancer cells, enabling clients to help patients develop selectively stronger immunity against certain carcinogenic substances and against cancer cells.
Contact Information
Website
www.tkg-na.comCorporate Office
- Entrepreneur Lab, South Research Building The University of Tokyo
- 7-3-1 Hongo, Bunkyo-ku
- Tokyo, Bunkyo-ku 113-8485
- Japan
Corporate Office
- Entrepreneur Lab, South Research Building The University of Tokyo
- 7-3-1 Hongo, Bunkyo-ku
- Tokyo, Bunkyo-ku 113-8485
- Japan
TKG (Drug Discovery) Timeline
TKG (Drug Discovery) Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Accelerator/Incubator | 01-Jun-2025 | Completed | Generating Revenue | |||
| 7. Seed Round | 31-Jan-2024 | Completed | Generating Revenue | |||
| 6. Accelerator/Incubator | 13-Sep-2023 | Completed | Startup | |||
| 5. Debt - General | 23-Jun-2023 | Completed | Startup | |||
| 4. Accelerator/Incubator | 01-Jan-2023 | Completed | Startup | |||
| 3. Accelerator/Incubator | Completed | Startup | ||||
| 2. Accelerator/Incubator | 01-Jan-2023 | Completed | Startup | |||
| 1. University Spin-Out | 01-Apr-2022 | Completed | Startup |
TKG (Drug Discovery) Patents
TKG (Drug Discovery) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025257997-A1 | Method for synthesizing oligo- or poly-nucleotides | Pending | 12-Jun-2024 | ||
| JP-2025022473-A | Method for extracting nucleic acid, composition, and cosmetic composition | Pending | 03-Aug-2023 | ||
| JP-2024149267-A | Method for synthesizing oligo- or polynucleotides | Pending | 07-Apr-2023 | ||
| JP-2024138694-A | Method for producing hairpin nucleic acid | Pending | 27-Mar-2023 | ||
| US-20260232716-A1 | Nucleic acid assembly pharmaceutical | Pending | 07-Feb-2023 | A61K31/7125 |
TKG (Drug Discovery) Signals
TKG (Drug Discovery) Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Plug and Play | Accelerator/Incubator | |||
| Mitsubishi Gas Chemical | Corporation | Minority | ||
| UntroD | Venture Capital | Minority | ||
| Japan External Trade Organization | Accelerator/Incubator | |||
| G-STARTUP | Accelerator/Incubator |
TKG (Drug Discovery) FAQs
-
When was TKG (Drug Discovery) founded?
TKG (Drug Discovery) was founded in 2022.
-
Where is TKG (Drug Discovery) headquartered?
TKG (Drug Discovery) is headquartered in Tokyo, Japan.
-
What is the size of TKG (Drug Discovery)?
TKG (Drug Discovery) has 2 total employees.
-
What industry is TKG (Drug Discovery) in?
TKG (Drug Discovery)’s primary industry is Drug Discovery.
-
Is TKG (Drug Discovery) a private or public company?
TKG (Drug Discovery) is a Private company.
-
What is TKG (Drug Discovery)’s current revenue?
The current revenue for TKG (Drug Discovery) is .
-
How much funding has TKG (Drug Discovery) raised over time?
TKG (Drug Discovery) has raised $1.53M.
-
Who are TKG (Drug Discovery)’s investors?
Plug and Play, Mitsubishi Gas Chemical, UntroD, Japan External Trade Organization, and G-STARTUP are 5 of 8 investors who have invested in TKG (Drug Discovery).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process